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Abstract 
 Transforming growth factor beta (TGF-β) plays an important role in carcinogenesis. Two 
polymorphisms in the TGF-β1 gene (-509C/T and 869T/C) were described to influence susceptibility to gastric 
and breast cancer. The 869T/C polymorphism was also associated with overall survival in breast cancer patients. 
In the present study we investigated the relevance of these TGF-β1 polymorphisms in glioma risk and prognosis. 
A case-control study that included 114 glioma patients and 138 cancer-free controls was performed. Single 
nucleotide polymorphisms (SNPs) were evaluated by polymerase chain reaction followed by restriction 
fragment length polymorphism (PCR-RFLP). Univariate and multivariate logistic regression analyses were 
used to calculate odds ratio (OR) and 95% confidence intervals (95% CI). The influence of TGF-β1 -509C/T 
and 869T/C polymorphisms on glioma patient survival were evaluated by a Cox regression model adjusted for 
patients’ age and sex, and represented in Kaplan-Meier curves. Our results demonstrated that TGF-β1 gene 
polymorphisms -509C/T and 869T/C are not significantly associated with glioma risk. Survival analyses 
showed that the homozygous -509TT genotype associates with longer overall survival of glioblastoma (GBM) 
patients when compared with patients carrying CC+CT genotypes (OR, 2.41; 95% CI, 1.06-5.50; p = 0.036). 
In addition, the homozygous 869CC genotype is associated with increased overall survival of GBM patients 
when compared with 869TT+TC genotypes (OR, 2.62; 95% CI, 1.11-6.17; p = 0.027). In conclusion, this study 
suggests that TGF-β1 -509C/T and 869T/C polymorphisms are not significantly associated with risk for 
developing gliomas, but may be relevant prognostic biomarkers in GBM patients. 
 
Keywords: Glioma; Glioblastoma; Transforming growth factor beta 1; Single nucleotide polymorphisms; Risk; 
Prognosis  
 
  
3 
 
Introduction 
 During the last decades, the incidence and mortality of brain tumors have increased in most developed 
countries, mainly in the older age groups, with a slightly higher incidence in men than in women [1]. Gliomas, 
the most common primary tumors of the central nervous system (CNS), account for almost 80% of brain 
malignancies [2]. According to their histological characteristics, these tumors can be divided into 4 main 
subgroups: astrocytomas, oligodendrogliomas, oligoastrocytomas and ependymomas (the less common). 
Glioma tumors can also be divided into 4 grades of malignancy according to the World Health Organization 
(WHO) classification, being glioblastoma (GBM) the most common and biologically aggressive glioma type 
(grade 4) [3, 4]. Despite the advances in the field of neuro-oncology, the prognosis of glioma patients remains 
very poor [5], particularly for patients with GBM [6]. Few factors have been associated with increased glioma 
risk, including hereditary syndromes, such as Li-Fraumeni and Turcot syndromes, neurofibromatosis (type 1 
and type 2) and tuberous sclerosis complex [7, 8], familial aggregation [7, 9], and exposure to high doses of 
ionizing radiation [7, 10, 11]. Some genome-wide association studies have showed that single nucleotide 
polymorphisms (SNPs) are associated with glioma susceptibility [12, 13]. However, other factors that may 
contribute to glioma susceptibility require additional investigation. 
 The transforming growth factor beta (TGF- β), a multifunctional cytokine, is involved in the regulation 
of several immunomodulatory processes that play a key role in numerous cellular processes, such as 
proliferation, differentiation, apoptosis, angiogenesis, tumor progression and extracellular matrix production 
[14]. TGF-β has three isoforms, TGF-β1, TGF-β2, and TGF-β3. These three isoforms bind and activate a 
membrane receptor serine/threonine complex (type I - TGFβRI and type II - TGFβRII). The intracellular 
signaling is initiated when TGFβRII phosphorylates TGFβRI, which in turn phosphorylates the transcription 
factors Smad2 or Smad3 that consequently bind Smad4. This complex is translocated from the cytoplasm to the 
nucleus, resulting in the transcriptional activation of TGF-β responsive genes that ultimately mediate the effects 
of TGF-β at the cellular level [15]. Deregulation of TGF-β signaling has been implicated in cancer, where TGF-
β has been demonstrated to have a dual role. It may act as a strong inhibitor of proliferation of normal astrocytes 
and epithelial cells, being considered a tumor suppressor factor, but in some tumor types, including high-grade 
glioma, TGF-β acts as an oncogenic factor contributing to cell growth and invasion, and decreases host immune 
responses against tumor [16]. It was also demonstrated that TGF-β activity confers poor prognosis in glioma 
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patients [17, 18]. Several studies have identified TGF-β1 as a predictive cancer biomarker, particularly focusing 
on TGF-β1 genetic polymorphisms [19-22]. In fact, it was demonstrated that polymorphisms in this gene 
contribute to breast and gastric cancers susceptibility [19, 23]. Additionally, studies demonstrated an association 
of TGF-β1 869T/C polymorphism with overall survival of breast cancer patients [24, 25]. The TGF-β1 gene is 
located on chromosome 19q13 and two common polymorphisms of the TGF-β1 gene have been extensively 
studied, the -509C/T (rs1800469) and the 869T/C (rs1800470, previously known as rs1982073; T29C and 
Leu10Pro) [22, 26, 27]. The -509C/T polymorphism is located in the promoter region of TGF-β1 gene, which 
may potentially regulate TGF-β1 transcription. The 869T/C polymorphism is located in exon 1 and could lead 
to a leucine-to-proline substitution at codon 10 [21, 26]. Some studies demonstrated that the -509T allele is 
associated with an increased transcriptional activity as compared to -509C allele [28], which leads to a higher 
serum concentration of TGF-β1 among TT homozygotes than in the CT heterozygotes [29]. Similarly, the 869C 
allele was associated with high serum concentrations of TGF-β1 [19, 30]. Moreover, some studies showed that 
-509C/T and 869T/C TGF-β1 polymorphisms were able to affect TGF-β1 protein expression [31, 32]. 
Importantly, the circulating levels of this cytokine have been associated with cancer [33-35]. The relevance of 
TGF-β1 polymorphisms has not been reported in gliomas. Thus, the aim of this case-control study was to 
investigate the relevance of TGF-β1 -509C/T and 869T/C polymorphisms in glioma susceptibility and how 
specific polymorphic variants may influence the prognosis of patients. 
 
 
Methods 
Study population 
 In this case-control study, we enrolled 114 glioma patients from Portugal (Hospital of Braga, Braga, 
and Hospital São João, Porto) diagnosed between 2004 and 2013. The peripheral blood from these subjects was 
collected. Tumors were classified according to WHO [3], and clinico-pathological features are summarized in 
Table 1. The control group was randomly selected from blood donors at Hospital of Braga, and it included 138 
cancer-free individuals. All subjects were of Caucasian ethnic background. The procedures followed in the 
present study were in accordance with institutional ethical standards.  
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Genotyping  
 Genomic DNA from glioma cases and controls was extracted from peripheral blood leukocytes by 
proteinase K/chloroform/isopropanol treatment [36]. The purified DNA was used to determine the genotypes 
of both polymorphisms, using polymerase chain reaction followed by restriction fragment length polymorphism 
(PCR-RFLP) methods. The PCR primers for -509C/T polymorphism were 5’-
CCCGGCTCCATTTCCAGGTG-3’ (forward) and 5’-GGTCACCAGAGAAAGAGGAC-3’ (reverse), and for 
the 869T/C polymorphism were 5’-CCTCCCCACCACACCAG-3’ (forward) and 5’-
CCGCAGCTTGGACAGG-3’ (reverse). The PCR was performed in a total volume of 25 μl containing 50 ng 
of DNA, 0.5 unit of KAPA Taq DNA polymerase (GRiSP), 1x KAPA Taq Buffer A containing MgCl2, 0.2 
mM dNTP Mix, and 0.8 µM of each primer. For the -509C/T polymorphism, the DNA was initially denatured 
at 95°C for 7 min, followed by 11 cycles of 95°C for 30 s, 66-61°C for 30 s, and 72°C for 1 min, followed by 
30 cycles of 95°C for 30 s, 61°C for 30 s, and 72°C for 1 min. The PCR was finished by a final extension cycle 
at 72°C for 8 min. Regarding 869T/C polymorphism, the PCR cycle conditions consisted of an initial 
denaturation step at 95°C for 5 min, followed by 9 cycles of 95°C for 30 s, 68-64°C for 30 s, and 72°C for 30 
s, followed by 30 cycles of 95°C for 30 s, 64°C for 30 s, and 72°C for 30 s. Finally, the PCR was completed by 
a final extension cycle at 72°C for 8 min. After confirmation of an amplified fragment of the expected size (808 
bp for -509C/T and 235 bp for 869T/C) on 2% agarose gel, 8-12 µL of PCR products were digested overnight 
at 37 °C with the appropriate restriction enzymes. For the -509C/T polymorphism, 10 units of restriction enzyme 
Bsu36I (New England Biolabs) were used, and for the 869T/C 5 units of the restriction enzyme MspA1I 
(Fermentas) were applied. The DNA fragments were resolved on 2% agarose gel for -509C/T polymorphism 
and 4% agarose gel for 869T/C polymorphism and were detected by Greensafe Premium staining (Nzytech). 
For -509C/T polymorphism, the PCR product (808 bp) with C allele was digested into two fragments (617 and 
191 bp), whereas the PCR product with T allele was not digested by Bsu36I. For 869T/C polymorphism, the 
PCR product (235 bp) with T allele was digested into four fragments (103, 67, 40, and 25 bp), and the PCR 
product with C allele was digested into five fragments (91, 67, 40, 25, and 12 bp).  
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Statistical analysis 
 Data analysis was performed using SPSS 22.0 software (SPSS, Inc.). Differences in allele and 
genotype frequencies were compared between glioma patients and cancer-free controls by the chi-square, and 
the frequency distribution of patients’ age and sex were compared between glioma patients and cancer-free 
controls by the non-parametric Wilcoxon-Mann Whitney test. Additionally, the chi-square test was used to 
verify that the observed allele distribution, in the control group, was in Hardy-Weinberg equilibrium. Odds ratio 
(OR) and 95% confidence intervals (95% CI) were estimated by univariate and multivariate logistic regression 
analyses, adjusted for patients’ age (as a continuous variable) and sex, to assess the risk for each glioma type 
conferred by a particular allele and genotype of each polymorphism. Patient survival curves were assessed by 
the Kaplan-Meier method for GBM. A Cox regression model adjusted for patients’ age (as a continuous 
variable) and sex was applied to evaluate the effect of the TGF-β1 genotypes on overall survival. Statistical 
significance was considered for p values < 0.05. 
 
 
Results 
 The clinico-pathological features of the controls and cases are summarized in Table 1. For both TGF-
β1 -509C/T and 869T/C polymorphisms, 114 glioma patients and 138 cancer-free control individuals were 
analyzed. The statistical analysis of age distribution between control and glioma cases showed significant 
differences (p ≤ 0.001). Regarding sex distribution, no significant differences were found between controls and 
cases (p = 0.195). The genotype and allele frequencies of the TGF-β1 -509C/T and 869T/C polymorphisms in 
controls and glioma cases are shown in Table 2. The frequencies of the CC, CT, and TT genotypes of -509C/T 
were 39.1%, 44.9%, and 16.0% in cancer-free controls, and 36.8%, 47.4%, and 15.8% in glioma patients, 
respectively. Regarding the 869T/C polymorphism, the frequencies of the TT, TC, and CC genotypes were 
34.8%, 46.4%, and 18.8% in controls, and 36.8%, 46.5%, and 16.7% in glioma cases, respectively. The 
distribution of -509C/T and 869T/C allele frequencies in the control group were in Hardy−Weinberg 
equilibrium (p = 0.891 and p = 0.685, respectively).  
 When assessing the allele frequencies of the TGF-β1 -509C/T polymorphism by univariate analysis, 
we found that the C allele was not significantly associated with a higher risk for glioma (OR, 0.97, 95% CI 
7 
 
0.68-1.39; Table 2). Additionally, using TT genotype as reference, the OR analysis showed that the CC, CT 
and combined CC+CT genotypes were not significantly associated with increased risk for glioma (OR 0.95, 
95% CI 0.45-1.98 for CC; OR 1.07, 95% CI 0.52-2.19 for CT; OR 1.01, 95% CI 0.51-2.00 for CC+CT; Table 
2). Evaluating the TGF-β1 869T/C polymorphism by univariate analysis, the T allele was not significantly 
associated with a higher risk for glioma (OR 1.09, 95% CI 0.76-1.56, Table 2). Using CC genotype as reference, 
the OR analysis showed that the TT, TC and combined TT+TC genotypes were not significantly associated 
with increased risk for glioma (OR, 1.20, 95% CI 0.58-2.47 for TT; OR 1.13, 95% CI 0.57-2.27 for TC; OR 
1.16, 95% CI 0.61-2.23 for TT+TC; Table 2). Taking into account that GBM were the most frequent subtype 
in our series (n = 85), we also compared the control group with GBM cases. Using similar analysis, a lack of 
association between both TGF-β1 -509C/T and 869T/C allele or genotype variants and risk for developing GBM 
was observed (Table 2). Moreover, for both polymorphisms, a multivariate logistic regression model adjusted 
for sex and age as a continuous variable (Table 3) was applied. As expected, increased age was associated with 
increased risks for developing glioma and GBM. Similarly, female gender was associated with decreased risks 
(Table 3). Consistent with the results observed by the univariate analysis, no associations between each 
polymorphic variant and risk for developing gliomas or GBMs were found (Table 3).  
 We then evaluated whether these TGF-β1 polymorphisms may have an impact in patients’ survival. 
To do so, we focused exclusively in GBM patients with available survival data (n = 44), as glioma grade is a 
strong influencer of survival, precluding an analysis in the whole glioma dataset. Regarding -509C/T 
polymorphism, the Cox model showed that GBM patients carrying the TT genotype had significantly increased 
overall survival compared to those with the CC+CT genotypes (OR 2.41, 95% CI 1.06-5.50, Table 4; p = 0.036, 
Fig.1a). Moreover, patients with CT genotype alone presented a shorter overall survival when compared to 
those carrying TT genotype (OR 2.72, 95% CI 1.12-6.65, Table 4; p = 0.028, Fig. 1b). No significant differences 
in overall survival were found in GBM patients with TGF-β1 -509CC versus TT genotypes (Table 4). 
Concerning the survival analysis for the TGF-β1 869T/C polymorphism, the Cox regression model 
demonstrated that TT+TC genotypes were significantly associated with shorter survival in GBM patients, as 
compared to the CC genotype (OR 2.62, 95% CI, 1.11-6.17, Table 4; p = 0.027, Fig.1c). These results were 
further supported when we compared patients with TC genotype with patients carrying the CC genotype (OR 
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2.71, 95% CI 1.12-6.54, Table 4; p = 0.027, Fig.1d). No significant differences in overall survival were found 
in GBM patients with TGF-β1 869CC versus TT genotypes (Table 4). 
 
 
Discussion 
 Gliomagenesis is a complex and poorly understood process in which genetic and environmental factors 
play critical roles. Several studies have suggested that SNPs are the most common sources of human genetic 
variation, and they may contribute to individual’s susceptibility to cancer, including glioma [37]. So far, SNPs 
of several genes have been studied and identified as putative biomarkers for glioma susceptibility. Some 
examples include genes encoding proteins involved in DNA repair pathways (MGMT, PRKDC, ERCC1, 
XRCC1, APEX1, TP53, PARP1, and LIG1) [38-41], cancer metabolism (GST, CYP2D6, SOD2, SOD3, GPX1 
and NOS1) [42, 43], growth pathways [44, 45], among others [46, 47]. Many association studies on the TGF-
β1 polymorphisms have been conducted in several types of cancer, including lung [27], prostate [20, 26], gastric 
[21], hepatocellular [22] and breast cancers [19, 24, 30, 48]. To the best of our knowledge, this is the first study 
to evaluate the TGF-β1 -509C/T and 869T/C polymorphisms in glioma patients. This is particularly relevant as 
these two polymorphisms have been reported to affect TGF-β1 protein expression and influence the structure 
and function of TGF-β1 peptide which may contribute to cancer [31, 32]. 
 Using both univariate and multivariate statistical analyses, our results showed that none of the TGF-
β1 -509C/T and 869T/C polymorphisms are significantly associated with glioma susceptibility. These data fit 
well with previous studies in other tumor types in which 869T/C was not associated with breast cancer risk 
[48], and -509C/T polymorphism was not associated with an increased risk of colorectal cancer [49]. While in 
our dataset we included solely patients of Caucasian background, future studies should evaluate how these TGF-
β1 polymorphisms may have relevance in other ethnic backgrounds, as previously suggested for many other 
polymorphisms [50-53].  
 It has been described that TGF-β1 contributes to cell growth, angiogenesis, and invasion, is highly 
active and confers poor prognosis in high-grade glioma patients [16-18]. Therefore, it is conceivable that 
patients carrying the T allele of the -509C/T polymorphism and patients with the C allele of the 869T/C 
polymorphism may have reduced cancer survival, since both these alleles are associated with an elevated TGF-
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β1 levels. Contrarily, in our study, GBM patients carrying TT genotype of the -509C/T polymorphism and 
patients with CC genotype of 869T/C polymorphism presented longer overall survival. This is in agreement 
with a previous work where it has been shown that breast cancer patients carrying the CC genotype of the 
869T/C polymorphism presented a longer overall survival [24]. Therefore, the TT genotype of the -509C/T 
polymorphism and the CC genotype of the 869T/C polymorphism have the potential to be used as predictive 
marker of better survival in patients with GBM. Additionally, taking into account that -509T allele has been 
suspected to increase the transcription of TGF-β1, patients that present this variant may be more suited for an 
anti-TGF-β1 monoclonal antibody therapy (Metelimumab) [54]. It remains, however, to be seen if -509C/T and 
869T/C polymorphisms are in a linkage disequilibrium and if it is functionally relevant. For instance, it has 
been shown that these two TGF-β1 polymorphisms (-509C/T and 869T/C) are in strong linkage disequilibrium 
in breast cancer patients, although it remains to be determined which of the two polymorphisms is functionally 
significant and affect survival [25]. 
 In conclusion, this study shows that TGF-β1 -509C/T and 869T/C polymorphisms do not confer 
susceptibility to develop glioma but may have an impact in the survival of GBM patients. Specifically, the TGF-
β1 -509TT and 869CC genotypes can be used as predictive markers of improved survival. In the future, 
additional studies with larger datasets will be needed to extend and validate these novel findings. 
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Table 1 Clinico-pathological features of gliomas and controls 
Groups (WHO grade) No. Cases Age, y (mean ± SD) Male/Female Ratio 
Controls 138 40.9 ± 12.1 1.2 
Gliomas (2-4) 114 58.3 ± 12.9 1.7 
   Astrocytomas (2-4) 97 58.9 ± 12.7 2.2 
      Astrocytomas (2-3) 8 52.3 ± 13.3 1 
          Diffuse astrocytoma (2) 5 54.8 ± 13.8 0.67 
          Anaplastic astrocytoma (3) 2 55.0 ± 9.9 1 
     Gliosarcomas (4) 4 61.3  ± 9.1 All males 
      Glioblastoma (4) 85 59.5 ± 12.7 2.1 
   Oligodendrogliomas (2-3) 16 53.1  ± 12.3 0.45 
      Oligodendroglioma (2) 4 46.3 ± 9.7 All females 
      Anaplastic Oligodendroglioma (3) 10 54.7 ± 12.9 0.67 
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Table 2 Univariate analysis of the association between -509C/T and 869T/C 
polymorphisms and risk for each glioma group 
Polymorphism Control 
Glioma 
(WHO grades 2-4) 
aOR (95% CI) 
Glioblastoma 
(WHO grade 4) 
aOR (95% CI) 
TGF-β1 -509C/T  
Genotypes      
TT 22 18 - 16 - 
CC 54 42 0.95 (0.45-1.98) 28 0.71 (0.32-1.57) 
CT 62 54 1.07 (0.52-2.19) 41 0.91 (0.43-1.94) 
CC+CT 116 96 1.01 (0.51-2.00) 69 0.82 (0.40-1.66) 
Alleles      
T 0.384 0.395 - 0.429 - 
C 0.616 0.605 0.97 (0.68-1.39) 0.571 0.85 (0.57-1.25) 
TGF-β1 869T/C      
Genotypes      
CC 26 19 - 17 - 
TT 48 42 1.20 (0.58-2.47) 30 0.96 (0.45-2.05) 
TC 64 53 1.13 (0.57-2.27) 38 0.91 (0.44-1.89) 
TT+TC 112 95 1.16 (0.61-2.23) 68 0.93 (0.47-1.84) 
Alleles      
C 0.420 0.399 - 0.424 - 
T 0.580 0.601 1.09 (0.76-1.56) 0.576 1.10 (0.75-1.64) 
aOdds ratio (OR) with 95% confidence intervals (CI). 
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Table 3 Multivariate logistic regression analysis of the association between -509C/T and 869T/C 
polymorphisms and risk for each glioma group 
Polymorphism Control 
Glioma  
(WHO grade 2-4) 
aOR (95% CI) 
Glioblastoma 
(WHO grade 4) 
aOR (95% CI) 
TGF-β1 -509C/T      
Genotypes      
TT 22 17 - 15 - 
CC 54 40 1.14 (0.45-2.98) 27 0.76 (0.27-2.13) 
CT 62 52 1.11 (0.45-2.75) 39 0.82 (0.30-2.21) 
CC+CT 116 92 1.13 (0.48-2.63) 66 0.79 (0.31-2.01) 
Alleles      
T 0.384 0.394 - 0.426 - 
C 0.616 0.606 1.08 (0.68-1.70) 0.574 0.89 (0.53-1.48) 
Age   1.12 (1.09-1.15)  1.14 (1.10-1.18) 
Sex      
Male 76 69 - 58 - 
Female 62 40 0.40 (0.20-0.77) 27 0.24 (0.11-0.52) 
TGF-β1 869T/C      
Genotypes      
CC 26 17 - 15 - 
TT 48 40 1.36 (0.55-3.34) 29 0.89 (0.33-2.41) 
TC 64 52 1.12 (0.47-2.66) 37 0.80 (0.31-2.07) 
TT+TC 112 92 1.22 (0.55-2.73) 66 0.84 (0.35-2.02) 
Alleles      
C 0.420 0.394 - 0.414 - 
T 0.580 0.606 1.19 (0.75-1.87) 0.586 1.09 (0.64-1.84) 
Age   1.12 (1.09-1.15)  1.14 (1.10-1.18) 
Sex      
Male 76 69 - 58 - 
Female 62 40 0.39 (0.20-0.76) 27 0.24 (0.11-0.52) 
aOdds ratio (OR) with 95% confidence intervals (CI), adjusted for age (as a continuous variable) and sex. Bold-faced values indicate 
significant differences at 5% level. 
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Table 4 Multivariate COX regression analysis of the 
association between -509C/T and 869T/C 
polymorphisms and survival in grade 4 gliomas 
Polymorphism n aOR (95% CI) 
TGF-β1 -509C/T   
Genotypes   
TT 12 - 
CC 16 2.09 (0.83-5.31) 
CT 16 2.72 (1.12-6.65) 
CC+CT 32 2.41 (1.06-5.50) 
Age  1.02 (0.99-1.05) 
Sex   
Male 31 - 
Female 13 1.13 (0.52-2.45) 
TGF-β1 869T/C   
Genotypes   
CC 12 - 
TT 14 2.43 (0.88-6.70) 
TC 18 2.71 (1.12-6.54) 
TT+TC 32 2.62 (1.11-6.17) 
Age  1.01 (0.99-1.04) 
Sex   
Male 31 - 
Female 13 1.28 (0.57-2.89) 
 aOdds ratio (OR) with 95% confidence intervals (CI), adjusted 
for age (as a continuous variable) and sex. Bold-faced values 
indicate significant differences at 5% level.  
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Figure Legend 
 
Fig. 1 Effect of TGF-β1 -509C/T and 869T/C polymorphisms in the survival of glioblastoma patients 
Kaplan-Meier overall survival curves for TGF-β1 -509C/T (a and b) and 869T/C (c and d) polymorphisms. In 
the -509C/T polymorphism, Cox regression analysis showed that the group of glioblastoma patients harboring 
CC+CT genotypes (a, p = 0.036) or patients with CT genotype (b, p = 0.028) had statistically significant shorter 
overall survivals when compared to patients with TT genotype. Regarding the 869T/C polymorphism, the group 
of glioblastoma patients with TT+TC genotypes (c, p = 0.027) or patients with TC genotype (d, p = 0.027) had 
significantly shorter overall survivals than patients with CC genotype. Tick marks indicate censored data 
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